Drug Type Small molecule drug |
Synonyms NTX 301, XNTR-20-02 |
Target |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 2 | AU | 30 Jan 2022 | |
Bladder Cancer | Phase 2 | AU | 30 Jan 2022 | |
Advanced Malignant Solid Neoplasm | Phase 2 | AU | 25 Aug 2021 | |
High grade glioma | Phase 2 | AU | 25 Aug 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | AU | 25 Aug 2021 | |
Urogenital Neoplasms | Phase 2 | AU | - | 28 Jun 2021 |
Glioma | Phase 2 | AU | 01 May 2021 | |
Ovarian Cancer | Phase 2 | AU | 01 May 2021 | |
Transitional Cell Carcinoma | Phase 2 | AU | 01 May 2021 | |
Chronic Myelomonocytic Leukemia | Phase 1 | US | 29 Dec 2020 |